Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современные фторхинолоны в лечении распространенного перитонита
Современные фторхинолоны в лечении распространенного перитонита
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Solomkin JS, Mazuski JE, Baron EJ et al Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997–1005.
2. Костюченко К.В. Прогнозирование исходов хирургического лечения распространенного перитонита. Автореф. дис. ... д-р мед. наук. Ярославль, 2009.
3. Sendl W et al. Presented at 12th ECCMID. Milan, 2002.
4. Козлов Р., Козлов С., Голуб А. Фторхинолоны с антианаэробной активностью при полимикробных инфекциях. Врач. 2009; с. 25–8.
5. Mosdell DM, Morris DM, Voltura A et al Antibiotic treatment for surgical peritonitis. Ann Surg 1991; 214: 543–9.
6. Neuhauser MM, Weinstein RA, Rydman R et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolones. JAMA 2003; 289; 885–8.
7. Carmelli Y. The role of carbapanems. The predictive factors for multi-drug resistant gram-negatives 2006.
8. Burkhardt O, Welte T. 10-летний опыт применения фторхинолона IV поколения моксифлоксацина. Expert Rev Anti Infect Ther 2009; 7 (6): 645–68.
9. Bebear CM, Barbeyrac B, Pereyre S et al. Activity of moxifloxacin against the urogenital mycoplasmas. Clin Microbiol Infect 2008; 14 (8): 801–5.
10. Malangoni MA, Song J, Herrington J et al Randomized controlled trials of moxofloxacin compared with piperazillin/tazobactam and amoxicillin-clavulanate for the treatment of complicated intraabdominal infections. Ann Surg 2006; 244 (2): 204–11.
11. Ross J, Cronje H, Paskowski T et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomized trial. Sex Transm Infect 2006; 82: 446–51.
12. Weiss G, Rimnitz P, Hampel B et al. The AIDA Study Group. Moxifloxacin for the treatment of patients with complicated intraabdominal infections. J Chemother 2009; 21 (2): 170–80.
13. Heystek MJ, Tellarini M, Schnitz H, Krasemann C. Efficacy and safety of moxifloxacin versus ciprofloxacin plus doxycyclin plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009.
14. Mu YP, Liu RL, Wang LO et al. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analyses of randomized controlled trials. Int J Clin Practice 2012; 66 (2): 210–7.
15. Chris Berrie. Moxifloxacin noninferior to carbapenem Ertapenem in treating complicated intra-abdominal infections. Presented at ECCMID. Results of PROMISE study. Vienna, 2010.
16. Goldstein EJ, Citon DM, Peraino V. Effect on antimicrobial usage and the in vitro susceptibility on aerobic gram-negative rods after the introduction of ertapenem onto a hospital formulary. Abstracts of the Forthy-fourth Infections Disease Society of America. Toronto, Canada, 2006; Abstract 280: p. 98.
17. Брискин Б.С., Дибиров М.Д., Хачатрян Н.Н. Антибактериальная терапия тяжелых форм распространенного перитонита. Cons. Med., 2006.
18. Гостищев В.К., Сажин В.П., Авдовенко А.Л. Перитонит. М., 2002.
19. Савельев В.С., Гельфанд Б.Р., Филимонов М.Н. Перитонит. Практическое руководство. 2006.
20. Cornaglia G, Hryniewich W, Jarlier V et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10: 349–83.
21. Edminston CE, Krepel CJ, Seabrook GR et al. In vivo activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intraabdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48 (3): 1012–6.
22. Hermsen ED, Hovde LB, Sprandel KA et al. Levofloxacin plus metronidazole administered once daily versus Moxifloxacin Monotherapy against mixed infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic Model. Antimicrob Agents Chemother 2005; 49 (2): 685–9.
23. Krobot K, Yin D, Zhang Q et al. Effect of inappropiate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur I Clin Microbiol Infect Dis 2004; 23: 682–7.
24. Pletz MW, Bloos F, Burkhardt O et al. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intens Care Med 2010; 36: 979–83.
25. Strass H, Rink AO, Delesen H et al Pharmacokinetics and peritoneal penetration of Moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58: 693–6.
2. Костюченко К.В. Прогнозирование исходов хирургического лечения распространенного перитонита. Автореф. дис. ... д-р мед. наук. Ярославль, 2009.
3. Sendl W et al. Presented at 12th ECCMID. Milan, 2002.
4. Козлов Р., Козлов С., Голуб А. Фторхинолоны с антианаэробной активностью при полимикробных инфекциях. Врач. 2009; с. 25–8.
5. Mosdell DM, Morris DM, Voltura A et al Antibiotic treatment for surgical peritonitis. Ann Surg 1991; 214: 543–9.
6. Neuhauser MM, Weinstein RA, Rydman R et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolones. JAMA 2003; 289; 885–8.
7. Carmelli Y. The role of carbapanems. The predictive factors for multi-drug resistant gram-negatives 2006.
8. Burkhardt O, Welte T. 10-летний опыт применения фторхинолона IV поколения моксифлоксацина. Expert Rev Anti Infect Ther 2009; 7 (6): 645–68.
9. Bebear CM, Barbeyrac B, Pereyre S et al. Activity of moxifloxacin against the urogenital mycoplasmas. Clin Microbiol Infect 2008; 14 (8): 801–5.
10. Malangoni MA, Song J, Herrington J et al Randomized controlled trials of moxofloxacin compared with piperazillin/tazobactam and amoxicillin-clavulanate for the treatment of complicated intraabdominal infections. Ann Surg 2006; 244 (2): 204–11.
11. Ross J, Cronje H, Paskowski T et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomized trial. Sex Transm Infect 2006; 82: 446–51.
12. Weiss G, Rimnitz P, Hampel B et al. The AIDA Study Group. Moxifloxacin for the treatment of patients with complicated intraabdominal infections. J Chemother 2009; 21 (2): 170–80.
13. Heystek MJ, Tellarini M, Schnitz H, Krasemann C. Efficacy and safety of moxifloxacin versus ciprofloxacin plus doxycyclin plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009.
14. Mu YP, Liu RL, Wang LO et al. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analyses of randomized controlled trials. Int J Clin Practice 2012; 66 (2): 210–7.
15. Chris Berrie. Moxifloxacin noninferior to carbapenem Ertapenem in treating complicated intra-abdominal infections. Presented at ECCMID. Results of PROMISE study. Vienna, 2010.
16. Goldstein EJ, Citon DM, Peraino V. Effect on antimicrobial usage and the in vitro susceptibility on aerobic gram-negative rods after the introduction of ertapenem onto a hospital formulary. Abstracts of the Forthy-fourth Infections Disease Society of America. Toronto, Canada, 2006; Abstract 280: p. 98.
17. Брискин Б.С., Дибиров М.Д., Хачатрян Н.Н. Антибактериальная терапия тяжелых форм распространенного перитонита. Cons. Med., 2006.
18. Гостищев В.К., Сажин В.П., Авдовенко А.Л. Перитонит. М., 2002.
19. Савельев В.С., Гельфанд Б.Р., Филимонов М.Н. Перитонит. Практическое руководство. 2006.
20. Cornaglia G, Hryniewich W, Jarlier V et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10: 349–83.
21. Edminston CE, Krepel CJ, Seabrook GR et al. In vivo activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intraabdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48 (3): 1012–6.
22. Hermsen ED, Hovde LB, Sprandel KA et al. Levofloxacin plus metronidazole administered once daily versus Moxifloxacin Monotherapy against mixed infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic Model. Antimicrob Agents Chemother 2005; 49 (2): 685–9.
23. Krobot K, Yin D, Zhang Q et al. Effect of inappropiate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur I Clin Microbiol Infect Dis 2004; 23: 682–7.
24. Pletz MW, Bloos F, Burkhardt O et al. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intens Care Med 2010; 36: 979–83.
25. Strass H, Rink AO, Delesen H et al Pharmacokinetics and peritoneal penetration of Moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58: 693–6.
Авторы
Н.Н.Хачатрян, Н.К.Вабищевич, Б.Г.Муслимов, А.А.Вайсберг, А.А.Михайлин, Т.А.Фесенко
Кафедра хирургических болезней и клинической ангиологии ГОУ ВПО МГМСУ Минздрава РФ;
Городская клиническая больница №50, Москва
Кафедра хирургических болезней и клинической ангиологии ГОУ ВПО МГМСУ Минздрава РФ;
Городская клиническая больница №50, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.